Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups.
Renato Bassan(Pittini Group (Italy)), T Barbui, Michele Vespignani, Teresa Lerede, G Broccia, S Morandi, Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), T Izzi, P Spedini, Giorgio Lambertenghi‐Deliliers(Ospedale Maggiore), Paolo Casula, Giuseppe Rossi(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Enrico Pogliani(Azienda Ospedaliera San Gerardo), P Fabris, P Coser, G. Corneo, Gianmaria Borleri
Cited by 31
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627